IntelGenx Technologies (IGXT) has released an update.
IntelGenx has initiated a Phase 2 clinical trial called MONTPARK, administering Montelukast VersaFilm® to Parkinson’s Disease patients to explore its efficacy in slowing disease progression. This milestone marks a significant step in developing alternative treatments for neurodegenerative diseases. The trial will involve up to 90 patients over a period of 21 months, aiming to offer a novel treatment that improves upon current standards by potentially modifying the disease and enhancing patient compliance.
For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.